Item 1(a). | Name of Issuer: |
| ADMA Biologics, Inc. (the “Issuer”) |
Item 1(b). | Address of Issuer’s Principal Executive Offices: |
465 State Route 17
Ramsey, New Jersey 07446
Item 2(a). | Names of Persons Filing: |
The names of the persons filing this report (collectively, the “Reporting Persons”) are:
Perceptive Advisors LLC (“Perceptive Advisors”)
Joseph Edelman (“Mr. Edelman”)
Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)
Item 2(b). | Address of Principal Business Office or, if None, Residence: |
The address of the principal business office of each of the Reporting Persons is:
51 Astor Place, 10th Floor
New York, NY 10003
Perceptive Advisors is a Delaware limited liability company
Mr. Edelman is a United States citizen
The Master Fund is a Cayman Islands corporation
Item 2(d). | Title of Class of Securities: |
Common Stock, par value $0.0001 per share (“Common Stock”)
000899 104
Item 3. | If this statement is filed pursuant to§§240.13d-1(b) or240.13d-2(b) or (c), checkwhether the person filing is a: |
Not applicable.
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on (i) 46,380,306 outstanding shares of Common Stock as disclosed by the Issuer in the Form10-Q filed on May 8, 2019, and (ii) 12,937,500 shares of Common Stock issued the Issuer’s public offering, as announced on May 21, 2019.